Does coffee truly boost memory and focus or is it all hype?

These pieces of research are why I do coffee, nothing about memory or focus!

Has your incompetent? doctor still not installed a 24-hour coffee station in the hospital? Massive earlier research on the benefits of coffee here!

I'm not taking chances and do a 12 cup pot of coffee a day. 

How coffee protects against Parkinson’s Aug. 2014 

Coffee May Lower Your Risk of Dementia Feb. 2013

Coffee drinkers rejoice! Drinking coffee could lower the risk of Alzheimer’s disease 

And this: Coffee's Phenylindanes Fight Alzheimer's Plaque December 2018

New research suggests drinking coffee may reduce the risk of frailty May 2025

I think I'm in this category:  I never get the jitters or flushed skin.

Genetics determine how much coffee you can drink before it goes wrong

I'm doing a 12 cup pot of coffee a day with full fat milk to lessen my chances of dementia and Parkinsons. Tell me EXACTLY how much coffee to drink for that and I'll change. Yep, that is a lot more than the 400mg. suggested limit, I don't care! Preventing dementia and Parkinsons is vastly more important than whatever problems it can cause! 

Of course, your fuckingly incompetent? doctor did nothing with this from 2 years ago!

Dementia risk could drop by drinking just one shot daily of common beverage  August 2023

This line is great: The findings indicate that even the Espresso Martini cocktail contains the espresso's beneficial compounds - and can contribute to staving off dementia.

The latest here:

 Does coffee truly boost memory and focus or is it all hype?

A new narrative review unpacks how coffee may sharpen thinking and protect the brain while highlighting why its true mechanisms remain elusive.

Neurocognitive and Neurological Effects of Coffee and Caffeine: A Narrative Review. Image Credit: Igor_83 / Shutterstock

In a recent review published in the journal Cureus Journal of Medical Science, researchers examined the major chemical constituents of coffee and evaluated evidence from existing animal and human studies on their pain-relieving and cognitive benefits.

They concluded that coffee may offer cognitive, anti-inflammatory, and neuroprotective benefits. However, the diverse types of coffee, dosing patterns, and preparation methods make underlying mechanisms difficult to study, and the review emphasised that most evidence is associative rather than causal, and further study is needed.(I'm not waiting, Dementia and Parkinsons prevention are needed now. Not some 50 years in the future!)

Open Questions on Coffee Benefits

Epidemiological studies suggest that habitual coffee drinkers have lower risks of several neurodegenerative and cerebrovascular conditions, including Parkinson’s disease, Alzheimer’s disease, dementia, stroke, and multiple sclerosis.

Caffeine and related purine metabolites (theobromine, theophylline, and paraxanthine) are the best-known components, yet their precise roles in neuroplasticity, synaptic development, and neuronal signaling remain underexplored.

Caffeine influences multiple receptor systems, including adenosine, phosphodiesterase, and gamma-aminobutyric acid (GABA) receptors, but other caffeinated beverages do not consistently replicate coffee’s effects, suggesting coffee-specific synergies.

Given the aging global population, interest in coffee’s potential to enhance neuroprotection, memory, and cognitive performance has grown.

Experimental research in animals shows encouraging effects on memory, attention, and neurogenesis, but translating this to humans is complicated by the heterogeneity of coffee products and dosing patterns and by species differences in caffeine metabolism that limit generalisability from rodent models.

To map the current evidence, the authors conducted a narrative review. Broad searches in three medical databases retrieved 109 relevant peer-reviewed articles published in English in the past decade.

Coffee, Neuroplasticity, and Synaptic Function

Researchers found evidence of growing scientific interest in coffee’s relationship with neuroplasticity, the brain’s capacity to reorganize neural circuits through synaptic remodeling, long-term potentiation (LTP), long-term depression (LTD), and adult neurogenesis.

Aging reduces the brain’s plastic potential, making factors that maintain or enhance plasticity particularly important. Coffee constituents, especially caffeine, appear to influence several pathways involved in plasticity, including intracellular calcium regulation, receptor modulation, and neural oscillatory activity.

Understanding cultivated meat and its global potential eBook Discover how cultivated meat is transforming global food production through sustainable practices, ethical innovation, and cutting-edge technology.Download the latest edition

Evidence from animal studies indicates that caffeine can shift synaptic activity toward LTP, which supports learning and memory. However, studies also show that high or chronic caffeine exposure can attenuate LTP in the hippocampus, suggesting dose sensitivity and highlighting mechanistic uncertainty that remains unresolved in human studies.

Coffee and Human Brain Activity

Several trials reported improvements in vigilance, response time, memory accuracy, neural efficiency, and subjective alertness after consuming coffee, coffee fruit extracts, or combinations of coffee constituents with herbal supplements. These effects often appeared independent of caffeine dose, suggesting synergistic contributions from polyphenols although some trials reported neutral findings, underscoring variability across studies.

Studies also indicated benefits such as reduced fatigue, improved mood, and enhanced positive affect following regular coffee or coffee-berry extract consumption. Some interventions that combined sage or ginseng with coffee extracts produced additional benefits.

Additionally, beverages containing coffee berry extract or apple polyphenols increased cerebral blood flow and improved mood, hinting at a vascular or antioxidant contribution. Coffee can produce significant physiological, anxiety, and stress responses. 

Caffeine challenges in individuals with panic disorder induced panic symptoms in nearly half of participants, though this was not mediated by hypothalamic, pituitary, adrenal (HPA) axis activation. Conversely, coffee aroma reduced stress biomarkers and pulse rate during dental procedures. 

Regarding impacts on sleep, daily caffeine consumption in habitual coffee drinkers did not significantly alter sleep architecture, suggesting that they may adapt to its effects. Imaging studies under sleep deprivation show regional grey matter changes influenced by caffeine intake or withdrawal, highlighting coffee’s interaction with sleep-related brain plasticity. 

Population-based cohorts show that higher coffee or caffeine intake is associated with slower cognitive decline in older adults, especially women. The review notes that sex-specific hormonal interactions may contribute to these differences, though mechanisms remain unclear. 

Animal research supports caffeine’s neuroprotective roles in models of Alzheimer’s disease, metabolic disorders, stress, and seizures but results across human studies remain mixed.

Mechanisms Involving Adenosine

Caffeine’s neuroactive properties arise largely from antagonism of adenosine receptors, particularly A1 and A2A, which influence synaptic strength, neuronal excitability, inflammation, and energy balance.

Although caffeine binds all four adenosine receptors, many neuroplastic effects align most closely with A2A blockade. The review also discussed adenosine triphosphate (ATP) and adenosine as neuromodulators involved in neuroprotection, injury response, and neurodegenerative diseases.

Dysregulation of A2A and P2 receptors is implicated in Parkinson’s and Alzheimer’s disease, thus caffeine’s modulation of these pathways may underlie some epidemiological findings. 

The review also notes that caffeine’s analgesic actions, including enhanced analgesic bioavailability and modulation of nociceptive signaling, add an additional pathway through which coffee consumption may indirectly support cognitive function in people with chronic pain although this was presented as a secondary context rather than a primary mechanism of neuroprotection.

Conclusions

Current evidence suggests coffee may support cognition, neuroplasticity, and neuroprotection, but findings remain inconsistent.

Coffee’s effects are difficult to isolate because it contains many bioactive compounds, interacts with genetics and sex, and may be further modified by differences in caffeine metabolism, and is typically consumed within broader dietary patterns such as the Mediterranean diet.

Observational data show both benefits and potential risks at high intake levels, and results vary across neurodegenerative outcomes. 

However, this review’s narrative nature, reliance on heterogeneous and mainly observational studies, and limited control for factors such as bean type, preparation methods, and genetic differences in caffeine metabolism restrict firm conclusions and prevent determination of causality. 

Overall, coffee appears safe and possibly beneficial, but its mechanisms and optimal intake require more rigorous, controlled research.

Journal reference:

• Pergolizzi, J.V., Tenenbaum, J.T., Pergolizzi, C., LeQuang, J.A.K. (2025). Neurocognitive and Neurological Effects of Coffee and Caffeine: A Narrative Review. Cureus 17(10): e94742. DOI: 10.7759/cureus.94742, https://www.cureus.com/articles/407421-neurocognitive-and-neurological-effects-of-coffee-and-caffeine-a-narrative-review

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke

I wonder which of the 5 causes of the neuronal cascade of death this is addressing or is it something I haven't seen yet? 

Probably this: Chapter Thirteen - Adenosine Receptors in Cerebral Ischemia

The latest here:

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke

Theodore E. Liston, Ph.D., Vice President of Research, Astrocyte Pharmaceuticals Inc. (Photo: Business Wire)

• 
  
• 

April 10, 2023 08:00 AM Eastern Daylight Time

GROTON, Conn.--(BUSINESS WIRE)--Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today announced that Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Progress and Innovation Award from the journal Stroke for authoring one of the journal’s top three publications in 2022. The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.”

    “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.”
    Tweet this

Dr. Liston’s manuscript, Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke, demonstrates that Astrocyte’s proprietary AST-004 drug candidate targeting adenosine A1/A3 receptors is significantly efficacious in a primate model of ischemic stroke designed to simulate a human stroke Phase 2 trial. The study showed compelling benefits for AST-004 treatment slowing stroke lesion growth, preserving at risk penumbra tissue, and substantially reducing the amount of brain tissue lost to the stroke. The research included novel pharmacokinetic/pharmacodynamic (PK/PD) modeling enabling estimates of a recommended human dose.

“This research represents the first demonstration in primates that activation of specific adenosine receptors leads to significant efficacy in saving brain tissue at risk during a stroke,” remarked Dr. Liston. “This research was a truly international team effort throughout the design, planning, conduct, data analysis and publication, much of which happened during the challenging times of the COVID-19 pandemic, and will propel AST-004 into Phase 2 clinical studies.”

An interview with Dr. Liston regarding the research is available online conducted by Sarah Y. Song, M.D., M.P.H., Associate Professor in the Section of Cerebrovascular Disease in the Department of Neurological Sciences at Rush University Medical Center, and Stroke Digital Media Editor.

The Progress and Innovation Award is given to the publication’s first author and is comprised of a cash prize and a trophy. The award is made possible by funding from the American Heart Association | American Stroke Association.

Co-authors of the publication include Aldric Hama, Ph.D.; Johannes Boltze, M.D., Ph.D.; Russell B. Poe, Ph.D.; Takahiro Natsume, Ph.D.; Ikuo Hayashi, Ph.D.; Hiroyuki Takamatsu, Ph.D.; William S. Korinek, Ph.D.; and James D. Lechleiter, Ph.D., representing Astrocyte Pharmaceuticals and the University of Texas Health San Antonio in the USA, Hamamatsu Pharma Research in Japan, and the University of Warwick in the UK.

“The ongoing excitement of endovascular reperfusion has heralded a resurgence of scientific development aimed at improving acute stroke outcomes. The prestigious awarding of this year’s Stroke Progress & Innovation prize to Dr. Liston’s paper in Stroke, the flagship cerebrovascular journal of the American Heart Association, embodies this enthusiasm,” added Kevin Sheth, M.D., Chief of Yale’s Division of Neurocritical Care & Emergency Neurology, Director of the Yale Center of Brain & Mind Health, and Chief Medical Advisor to Astrocyte. “The paper is exciting because a novel concept, astrocyte protection, is tested in a non-human primate model of stroke that closely mirrors the clinical condition, and the positive results set the stage for immediate clinical translation.”

AST-004 is currently being evaluated in Phase 1B human safety studies, with Phase 2 efficacy studies in stroke patients planned to start in 2024.  

Adenosine and Astrocytes Control Critical Periods of Neural Plasticity

I guess you'll have to have your doctor get this article AND write a protocol on neuroplasticity so it can be repeatable on demand. 

Adenosine and Astrocytes Control Critical Periods of Neural Plasticity

Irene Martínez-Gallego and Antonio Rodríguez-Moreno https://orcid.org/0000-0002-8078-6175 arodmor@upo.esView all authors and affiliations

OnlineFirst

https://doi.org/10.1177/10738584221126632

• 
  

• 
  
• Get access
• • Cite article
  • Share options
  • Information, rights and permissions
  • Metrics and citations

Abstract

Windows of plasticity are fundamental for the correct formation of definitive brain circuits; these periods drive sensory and motor learning during development and ultimately learning and memory in adults. However, establishing windows of plasticity also imposes limitations on the central nervous system in terms of its capacity to recover from injury. Recent evidence highlights the important role that astrocytes and adenosine seem to play in controlling the duration of these critical periods of plasticity.

Get full access to this article

Tired? 4 simple ways to boost energy

Has your doctor validated that these ideas from Harvard Medical school help stroke fatigue? 

Tired? 4 simple ways to boost energy

Posted September 07, 2018, 6:30 am

Matthew Solan
Executive Editor, Harvard Men's Health Watch

When I’m dragging and feeling tired during the occasional low-energy day, my go-to elixir is an extra cup (or two or three) of black French press coffee. It gives my body and brain a needed jolt, but it may not help where I need it the most: my cells.

The cellular basis of being tired

What we call “energy” is actually a molecule called adenosine triphosphate (ATP), produced by tiny cellular structures called mitochondria. ATP’s job is to store energy and then deliver that energy to cells in other parts of the body. However, as you grow older, your body has fewer mitochondria. “If you feel you don’t have enough energy, it can be because your body has problems producing enough ATP and thus providing cells with enough energy,” says Dr. Anthony Komaroff, professor of medicine at Harvard Medical School. You may not be able to overcome all aspects of age-related energy loss, but there are ways to help your body produce more ATP and replenish dwindling energy levels. The most common strategies revolve around three basic concepts: diet, exercise, and sleep.
Diet. Boost your ATP with fatty acids and protein from lean meats like chicken and turkey, fatty fish like salmon and tuna, and nuts. While eating large amounts can feed your body more material for ATP, it also increases your risk for weight gain, which can lower energy levels. “The excess pounds mean your body has to work harder to move, so you use up more ATP,” says Dr. Komaroff. When lack of energy is an issue, it’s better to eat small meals and snacks every few hours than three large meals a day, according to Dr. Komaroff. “Your brain has very few energy reserves of its own and needs a steady supply of nutrients,” he says. “Also, large meals cause insulin levels to spike, which then drops your blood sugar rapidly, causing the sensation of fatigue.”
Drink enough water. If your body is short on fluids, one of the first signs is a feeling of fatigue. Although individual needs vary, the Institute of Medicine recommends men should aim for about 15 cups (3.7 liters) of fluids per day, and women about 12 cups (2.7 liters). Besides water and beverages like coffee, tea, and juices, you can also get your fluids from liquid-heavy fruits and vegetables that are up to 90% water, such as cucumbers, zucchini, squash, strawberries, citrus fruit, and melons.
Get plenty of sleep. Research suggests that healthy sleep can increase ATP levels. ATP levels surge in the initial hours of sleep, especially in key brain regions that are active during waking hours. Talk with your doctor if you have problems sleeping through the night.
Stick to an exercise routine. Exercise can boost energy levels by raising energy-promoting neurotransmitters in the brain, such as dopamine, norepinephrine, and serotonin, which is why you feel so good after a workout. Exercise also makes muscles stronger and more efficient, so they need less energy, and therefore conserve ATP. It doesn’t really matter what kind of exercise you do, but consistency is key. Some research has suggested that as little as 20 minutes of low-to-moderate aerobic activity, three days a week, can help sedentary people feel more energized.

When being tired warrants a visit to your doctor

You should see your doctor if you experience a prolonged bout of low energy, as it can be an early warning of a serious illness. “Unusual fatigue is often the first major red flag that something is wrong,” says Dr. Komaroff. Lack of energy is a typical symptom for most major diseases, like heart disease, many types of cancer, autoimmune diseases such as lupus and multiple sclerosis, and anemia (too few red blood cells). Fatigue also is a common sign of depression and anxiety. And fatigue is a side effect of some medications.

Related Information: Boosting Your Energy

Restoring auditory cortex plasticity in adult mice by restricting thalamic adenosine signaling

I would expect human testing to begin almost immediately. We need neuroplasticity up the wazoo since no one yet knows how to make neuroplasticity repeatable on demand. Of course that will never occur since we have NO stroke leadership and NO stroke strategy. 

Restoring auditory cortex plasticity in adult mice by restricting thalamic adenosine signaling

1. Jay A. Blundon¹,*,
2. Noah C. Roy¹,*,
3. Brett J. W. Teubner¹,
4. Jing Yu¹,
5. Tae-Yeon Eom¹,
6. K. Jake Sample¹,
7. Amar Pani¹,†,
8. Richard J. Smeyne¹,‡,
9. Seung Baek Han¹,
10. Ryan A. Kerekes²,
11. Derek C. Rose²,
12. Troy A. Hackett³,
13. Pradeep K. Vuppala⁴,§,
14. Burgess B. Freeman III⁴,
15. Stanislav S. Zakharenko¹,||

+ See all authors and affiliations

Science  30 Jun 2017:
Vol. 356, Issue 6345, pp. 1352-1356
DOI: 10.1126/science.aaf4612

• Article
• Figures & Data
• Info & Metrics
• eLetters
• PDF

You are currently viewing the abstract.
View Full Text

Via AAAS ID

This article is available to AAAS members. If you are a AAAS Member use your via AAAS ID and password to log in. Not a member? Click here to join.

---

• Join/Subscribe
• Purchase Article
• Activate Member Account
• Renew Subscription
• Recommend a subscription to your library
• Help for librarians

Order a single issue

Free with registration

Science research is available free with registration one year after initial publication. To get your free access please visit our registration form.

Abstract

Circuits in the auditory cortex are highly susceptible to acoustic influences during an early postnatal critical period. The auditory cortex selectively expands neural representations of enriched acoustic stimuli, a process important for human language acquisition. Adults lack this plasticity. Here we show in the murine auditory cortex that juvenile plasticity can be reestablished in adulthood if acoustic stimuli are paired with disruption of ecto-5′-nucleotidase–dependent adenosine production or A₁–adenosine receptor signaling in the auditory thalamus. This plasticity occurs at the level of cortical maps and individual neurons in the auditory cortex of awake adult mice and is associated with long-term improvement of tone-discrimination abilities. We conclude that, in adult mice, disrupting adenosine signaling in the thalamus rejuvenates plasticity in the auditory cortex and improves auditory perception.

Caterpillar fungi may benefit asthma patients

Its got anti-inflammatory properties and inflamation in the brain is a problem. Get your researcher involved.

When I was in Bhutan you could buy this, I didn't buy any. Ask your doctor what research they are doing on this.

All these benefits needing scientific proof. #6 seems really important.

Caterpillar fungi may benefit asthma patients

Research shows that cordycepin, extracted from a group of rare parasitic caterpillar fungi of the genus Cordyceps, has unusual anti-inflammatory properties that may make it a good candidate for treating conditions such as asthma and rheumatoid arthritis.
The investigators, led by Cornelia de Moor (University of Nottingham, UK), found that cordycepin, which is similar in structure to adenosine, inhibits the stimulation of inflammatory messenger RNAs (mRNAs) by cytokines secreted by smooth muscle cells in the human airway, but does not affect the expression of "housekeeping" mRNAs.
"We have shown that cordycepin reduces the expression of inflammatory genes in airway smooth muscle cells by acting on the final step in the synthesis of their messenger RNAs (mRNAs) which carry the chemical blueprint for the synthesis of proteins. This process is called polyadenylation," said de Moor in a press statement.
"However, it is a surprise that cordycepin does not affect the synthesis of mRNAs from other genes, because nearly all mRNAs require polyadenylation," she said.
Cordyceps fungi live on hibernating caterpillars in the Tibetan mountains and have been a highly sought after component of Chinese medicine for many years. Studies have suggested the fungi could be used to treat a variety of conditions including cancer, stroke, kidney disease, and inflammatory lung disease, but scientific evidence regarding the mechanism of action of cordycepin was unclear until now.

The scans that show how caffeine takes over your brain and stops you getting tired

So with my other major post on caffeine good vs. bad here; ask your doctor.
I however am going to continue to drink coffee.

The scans that show how caffeine takes over your brain and stops you getting tired

Last paragraphs but read the whole thing at the link;
Several investigations show that moderate coffee consumption of 3 to 5 cups per day at mid-life is linked to a reduced risk of dementia in late life.'

The team found that the repeated intake of caffeine can occupy up to 50 per cent of the brain's A1 adenosine receptors, stopping these from receiving the sleep-promoting neurotransmitter they were intended to absorb.
It is likely that this blockage of a substantial amount of cerebral A1 adenosine receptors will result in adaptive changes and lead to chronic alterations of receptor express and availability, they said.
They determined that it was this structure that may offer some insight as to why coffee drinkers were at lesser risk of dementia.
'The present study provides evidence that typical caffeine doses result in a high A1 adenosine receptor occupancy and supports the view that the A1 adenosine receptor deserves broader attention in the context of neurodegenerative disorders,' said Dr Elmenhorst, lead author of the study published in The Journal of Nuclear Medicine.